Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARADIGM CORPARDM · Entity 155143 | Director · Interim Principal Exec Ofcr | March 22, 2018 | March 26, 2018 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Director | February 23, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARADIGM CORP
Report date March 22, 2018 · Filed March 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 · Expires 2028-03-22 | Direct | 276,000 |
Reported balance
After 2018-03-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-22 · Grant · Acquired 276,000 · Balance 276,000 F1: Stock option vests (a) as to 96,000 shares on August 12, 2018 and (b) as to 180,000 shares in 36 equal monthly installments over a three-year period beginning on March 12, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option vests (a) as to 96,000 shares on August 12, 2018 and (b) as to 180,000 shares in 36 equal monthly installments over a three-year period beginning on March 12, 2018.
SUPERNUS PHARMACEUTICALS, INC.
Report date February 23, 2024 · Filed February 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,943 |
Reported balance
After 2024-02-23 transaction · row 1
1 source rowRow 1 · 2024-02-23 · Grant · Acquired 3,886 · Balance 87,943 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-23 · Disposition to issuer · Disposed 3,886 · Balance 0 F1: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F2: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2024 Filed Feb 27, 2024 17:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028277 · tm247055-19_4seq1.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,886 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. F2 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 17:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028277 · tm247055-19_4seq1.xml · nonDerivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,943 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 17:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027576 · tm247055-10_4seq1.xml · derivative · entry 3 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 17:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,252 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0001104659-24-027576 · tm247055-10_4seq1.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,252 Underlying: Common Stock · 8,252 shares Expires 2034-02-22 F1 · derivative.exercise_date: The option vests on February 22, 2025. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 17:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026073 · tm237737-12_4seq1.xml · derivative · entry 3 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,886 Underlying: Common Stock · 3,886 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 17:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,293 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026073 · tm237737-12_4seq1.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,293 Underlying: Common Stock · 6,293 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025383 · tm237737-5_4seq1.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025383 · tm237737-5_4seq1.xml · nonDerivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,057 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:26 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026880 · tm227622-6_4seq1.xml · derivative · entry 3 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,882 Underlying: Common Stock · 3,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:26 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,847 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026880 · tm227622-6_4seq1.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,847 Underlying: Common Stock · 6,847 shares Expires 2032-02-22 Read SEC document |
| February 19, 2022 Filed Feb 23, 2022 16:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026096 · tm227492-1_4seq1.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,222 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022. Read SEC document |
| February 19, 2022 Filed Feb 23, 2022 16:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026096 · tm227492-1_4seq1.xml · nonDerivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,175 Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-21-104206 · tm2124999-1_4seq1.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2021 Filed Aug 12, 2021 16:32 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001104659-21-104206 · tm2124999-1_4seq1.xml · nonDerivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-026930 · tm217706-5_4seq1.xml · derivative · entry 3 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,222 Underlying: Common Stock · 4,222 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. F2 · derivative.expiration_date: These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,365 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026930 · tm217706-5_4seq1.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 Underlying: Common Stock · 7,365 shares Expires 2031-02-19 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,305 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-20-024846 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,305 Underlying: Common Stock · 9,305 shares Expires 2030-02-21 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 5,211 | $23.99 | $125,011.89 |
DisclosureSEC source: 0001104659-20-024846 · a4.xml · nonDerivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,953 F1 · shares: Represents restricted stock unit component of the annual equity compensation to directors. These shares will be settled in common stock upon vesting, such vesting to occur on February 21, 2021. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:06 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-19-037264 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:06 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 10,000 | $9.13 | $91,300.00 |
DisclosureSEC source: 0001104659-19-037264 · a4.xml · nonDerivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 15:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-19-024504 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 15:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 10,000 | $9.13 | $91,300.00 |
DisclosureSEC source: 0001104659-19-024504 · a4.xml · nonDerivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,427 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-19-010794 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,427 Underlying: Common Stock · 12,427 shares Expires 2029-02-22 Read SEC document |
| February 22, 2019 Filed Mar 4, 2019 17:52 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,427 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-19-012549 · a4a.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,427 Underlying: Common Stock · 12,427 shares Expires 2029-02-22 Read SEC document |
| August 20, 2018 Filed Mar 4, 2019 17:41 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 7,457 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-19-012547 · a4.xml · derivative · entry 4 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,457 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2018 Filed Mar 4, 2019 17:41 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 8,722 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-19-012547 · a4.xml · derivative · entry 3 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,722 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2018 Filed Mar 4, 2019 17:41 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 7,457 | $9.24 | $68,902.68 |
DisclosureSEC source: 0001104659-19-012547 · a4.xml · nonDerivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2018 Filed Mar 4, 2019 17:41 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 8,722 | $7.90 | $68,903.80 |
DisclosureSEC source: 0001104659-19-012547 · a4.xml · nonDerivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:28 UTC | ARADIGM CORP ARDM · Entity 155143 | GrantStock Option (Right to Buy) · Derivative | 276,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001123292-18-000559 · edgar.xml · derivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director · Interim Principal Exec Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,000 Underlying: Common Stock · 276,000 shares Expires 2028-03-22 F1 · derivative.exercise_date: Stock option vests (a) as to 96,000 shares on August 12, 2018 and (b) as to 180,000 shares in 36 equal monthly installments over a three-year period beginning on March 12, 2018. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 17:46 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,613 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001104659-18-012893 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,613 Underlying: Common Stock · 8,613 shares Expires 2028-02-23 Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039594 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 17:55 UTC | ARADIGM CORP ARDM · Entity 155143 | GrantStock Option (Right to Buy) · Derivative | 110,485 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001123292-17-001083 · edgar.xml · derivative · entry 1 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,485 Underlying: Common Stock · 110,485 shares Expires 2027-06-01 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 1, 2017, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012171 · a4.xml · derivative · entry 2 SIEBERT JOHN M · CIK 0001190558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.